Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of ≤100/mm3: Demonstration of efficacy in a prospective, multicenter trial

Clinical Infectious Diseases

Volumn 23, Issue 6, 1996, Pages 1282-1286

  Singh, Nina ^b   Barnish, Michael J ^b   Berman, Steven ^b   Bender, Bradley S ^b   Wagener, Marilyn M ^b   Rinaldi, Michael G ^b   Yu, Victor L ^a  

^a VA Healthcare VISN 4   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0030472173     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.6.1282     Document Type: Article

References (17)

1. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
2. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995;345:548-52.
3. Monane M, Gurwitz JH, Monane S, Avorn J. Compliance issues in medical practice. Hosp Physician 1993;April:35-9.
4. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
5. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
6. Harris SC, Wallace JE, Foulds G, Rinaldi MG. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother 1989;33:714-6.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard. NCCLS document M27-T. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1995.
8. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4.
9. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
10. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. Oral Surg Oral Med Oral Pathol 1993;76:711-5.
11. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19:687-92.
12. Laguna F, Valencia E, Martinez-Suarez JV, Rodriguez-Tudela JL, Chaves F, Dronda F. Differences between fluconazole-resistant (FZR) and fluconazole-sensitive (FZS) oropharyngeal candidiasis in HIV+ patients [abstract 1213]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994.
13. Heald A, Cox G, Schell W, Bartlett J, Miralles D, Perfect J. Oropharyngeal yeast flora in human immunodeficiency virus (HIV) infected patients receiving long-term continuous fluconazole therapy [abstract 1227]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994.
14. Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995;39:1691-5.
15. DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993;37:2187-92.
16. Madu A, Cioffe C, Mian U, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid. Antimicrob Agents Chemother 1994;38:2111-5.
17. Wallace JE, Harris SC, Gallegos J, Foulds G, Chen TJ, Rinaldi MG. Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column. Antimicrob Agents Chemother 1992;36:603-6.